GoodRx Says First-Half 2026 Financials Can't Be Relied On, Will Restate

What happened

GoodRx Holdings, Inc., which runs a healthcare savings platform and marketplace for prescription drug discounts, disclosed in an SEC filing on November 2, 2026 that its Audit and Risk Committee concluded the company's financial statements for the quarter ended March 31, 2026 and the quarter ended June 30, 2026 should no longer be relied upon.

The filing, an 8-K filed under Item 4.02, attributes the problem to an understatement of "Pharma Direct revenue" — revenue from the company's pharmaceutical manufacturer business line. According to the filing, a portion of revenue was not recognized in each period that should have been under Accounting Standards Codification 606, the accounting standard governing revenue recognition.

The error understated total revenue by $7.5 million in the first quarter and by $22.3 million in the second quarter, or $29.8 million for the six months ended June 30, 2026. Restated six-month net income would be $24.6 million instead of the previously reported $9.7 million, and restated diluted earnings per share would be $0.07 instead of $0.03.

The committee reached its conclusion on October 27, 2026, after discussing the matter with management and with KPMG LLP, GoodRx's independent registered public accounting firm. The company said it has not identified any impact on financial statements for periods before fiscal 2026.

GoodRx said the figures are preliminary and may change as its review and restatement process concludes. It said it is working to file amended quarterly reports (Forms 10-Q) for the affected periods as soon as practicable, and it expects to report that one or more material weaknesses in internal control over financial reporting existed as of the end of each period.

The numbers

For the three months ended March 31, 2026: Pharma Direct revenue was reported as $52.2 million and is expected to be restated to $59.7 million; total revenue from $194.0 million to $201.5 million; operating income from $14.0 million to $19.3 million; net income from $1.2 million to $5.0 million.

For the three months ended June 30, 2026: Pharma Direct revenue was reported as $61.6 million and is expected to be restated to $83.9 million; total revenue from $200.4 million to $222.7 million; operating income from $23.6 million to $38.5 million; net income from $8.5 million to $19.6 million.

For the six months ended June 30, 2026: Pharma Direct revenue from $113.9 million to $143.6 million; total revenue from $394.4 million to $424.2 million; operating income from $37.6 million to $57.8 million; net income from $9.7 million to $24.6 million.

What this means

Item 4.02 of Form 8-K exists for exactly one situation: a company telling investors that financial statements it has already published — and that investors may have relied on — contain errors and should not be used. The trigger is a conclusion by the company's audit committee, the board committee responsible for overseeing financial reporting, typically reached after consultation with the outside auditor. The filing does not itself restate anything; it is a notice that a restatement is coming.

The accounting standard at issue, ASC 606, sets out when a company may record revenue. In general, revenue is recognized when a customer obtains control of a promised good or service, in the amount the company expects to be entitled to. For a business like GoodRx's Pharma Direct line — which involves transactions with pharmaceutical manufacturers — the timing question is when the company's performance obligation is satisfied, and therefore which quarter the revenue belongs in. Here the company says revenue that should have been recorded in the first half of 2026 was not.

This is not a case of money appearing or disappearing. The restatement moves revenue and profit into the periods where, under the company's revised reading of ASC 606, it belonged. That is why net income for the six months rises by $14.8 million while nothing about cash is disclosed as changing.

"Material weakness" is a specific term in auditing: a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement would not be prevented or detected on a timely basis. The company says it currently expects to report one or more such weaknesses for the affected periods. A company that reports a material weakness must also address it, though the filing does not describe a remediation plan.

The next concrete step the filing describes is the filing of amended Forms 10-Q for the two quarters, which will replace the earlier versions. The company cautions that the restatement amounts could change before those amendments are filed.

Market reaction

GoodRx Class A shares closed at $3.55 on the event date, up 1.72% from the prior close of $3.49, according to the price data provided. The filing was dated November 2, 2026, the same day as the price data.